Target intelligence / Profile preview

Paracrine-responsive endothelial and ischemic tissue milieu

Molecular classification
Other
01

Overview

The paracrine-responsive endothelial and ischemic tissue milieu refers to the specialized physiological microenvironment created within tissues experiencing chronic or acute oxygen deprivation. This milieu is characterized by the upregulation of hypoxia-inducible factors and the secretion of pro-angiogenic cytokines, which serve to recruit and activate cells capable of vascular repair. It is not a discrete molecular target like a receptor or enzyme, but rather a complex biological setting involving oxygen-deprived endothelial cells and a specific profile of secreted growth factors and cytokines. This milieu serves as the functional target for regenerative medicine approaches, particularly CD34+ cell therapies, which are designed to respond to local signals like SDF-1 and VEGF to promote the growth of new capillaries. By enhancing the natural angiogenic response within this environment, these therapies aim to restore blood flow in patients with conditions such as critical limb ischemia or refractory angina. The therapeutic strategy focuses on leveraging the existing paracrine signaling pathways to achieve microvascular expansion where traditional revascularization has failed.

Other names
Ischemic microenvironmentPro-angiogenic milieuIschemic tissue environment
02

Mechanism of action

Stimulation of microvascular expansion and angiogenesis through paracrine signaling and recruitment of progenitor cells within the ischemic environment.

03

Biological functions

AngiogenesisParacrine signalingTissue repairVasculogenesisHypoxia response
04

Disease associations

Critical limb ischemiaRefractory anginaPeripheral artery diseaseMyocardial infarctionCardiovascular disease
05

Safety considerations

Risk of pathological angiogenesis (e.g., retinopathy)Potential for tumor growth promotionDelivery challenges to poorly perfused tissuesInjection site reactions
06

Interacting drugs

CD34+ cell therapy (e.g., Honedra, CLBS12)

2 more in the full profile.

07

Biomarkers

Hypoxia-inducible factor 1-alpha (HIF-1α)Vascular endothelial growth factor (VEGF)Stromal cell-derived factor 1 (SDF-1)

Beyond the preview

Go deeper on Paracrine-responsive endothelial and ischemic tissue milieu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paracrine-responsive endothelial and ischemic tissue milieu.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call